ANTI-VIRAL IL-6 APPROACH TO MITIGATE KSHV-RELATED DISEASE

减轻 KSHV 相关疾病的抗病毒 IL-6 方法

• 批准号: 8357749
• 负责人: SCOTT W WONG
• 金额: $ 24.36万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357749
• 关键词: Adjuvant; Animals; Award; Biological; Chimeric Proteins; Control Animal; Disease; Exploratory/Developmental Grant for Diagnostic Cancer Imaging; Funding; Grant; Human Herpesvirus 8; Immune response; Interleukin-6; National Center for Research Resources; Open Reading Frames; Primates; Principal Investigator; Recombinants; Research; Research Infrastructure; Research Project Grants; Resources; Source; T cell response; United States National Institutes of Health; Vaccinated; Vaccination; Viral; Viral Physiology; Virus Diseases; cost; gammaherpesvirus; neutralizing antibody; novel; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This NIH R01 project was awarded in 2008-2009 and was derived from an NIH R21 award entitled; "Validating vIL-6 as a target for KSHV associated disease", which was an exploratory grant to investigate whether vIL-6 is necessary for RRV-associated disease. The focus of this research project is to investigate whether vaccination of RM with a novel vIL-6-Fc fusion protein is capable of inducing an immune response to inhibit the biological activity of viral IL-6. Analysis of animals vaccinated with the vIL-6-Fc fusion versus control animals given adjuvant alone indicates that vaccinated animals have a robust humoral response to RRV vIL-6. Second, a group of the vaccinated animals that was challenged with wild-type RRV have remained free of RRV-associated disease, despite evidence of virus infection. And finally, animals challenged with a recombinant RRV lacking the vIL-6 open reading frame and followed for virus infection and disease, were found to be free of RRV-associated disease. We have characterized the animals' immune responses to vIL-6 and have found that they possess neutralizing antibodies and T cell responses specific to vIL-6. We believe vaccination with vIL-6-Fc provides a novel and unique approach to inhibiting gamma-herpesvirus-associated disease

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 该NIH R01项目于2008 - 2009年授予，并源自NIH R21奖。 “将VIL-6验证为KSHV相关疾病的靶标”，这是研究VIL-6是否需要RRV相关疾病的探索性赠款。该研究项目的重点是研究用新型的VIL-6-FC融合蛋白对RM的疫苗接种是否能够诱导免疫反应以抑制病毒IL-6的生物学活性。单独给出的VIL-6-FC融合与对照动物接种疫苗接种的动物分析表明，接种疫苗的动物对RRV VIL-6具有强大的体液反应。其次，尽管有病毒感染的证据，但受到野生型RRV挑战的一组疫苗接种动物仍然没有与RRV相关的疾病。最后，发现缺乏VIL-6开放式阅读框的重组RRV挑战的动物，随后因病毒感染和疾病而没有RRV相关疾病。我们已经表征了动物对VIL-6的免疫反应，并发现它们具有中和抗体和T细胞反应对VIL-6的反应。我们认为使用VIL-6-FC疫苗接种提供了一种新颖而独特的方法来抑制与γ-HERPESVIRUS相关疾病